CVRx, Inc. (CVRX)

CVRx's stock price has experienced notable fluctuations, decreasing by 55.47% over the last 12 months and 17.30% in the past month. Key events include the announcement of Q4 2025 financial results, investor alerts from law firms investigating claims on behalf of CVRx investors, the initiation of the BENEFIT-HF trial, the report of preliminary Q4 and Fiscal Year 2025 financial results and Fiscal Year 2026 guidance, Q3 2025 earnings report, and seasonal softness impacting Q1 performance.

CVRx has observed a typical medical device seasonal pattern in its demand, characterized by a dip in performance during the first quarter (Q1) compared to the prior year's fourth quarter (Q4). This pattern is often influenced by patients scheduling their procedures around insurance coverage and deductibles.

CVRx, Inc. is a commercial-stage medical device company focused on developing and commercializing neuromodulation solutions for cardiovascular diseases, operating in the Healthcare sector, specifically the Medical Devices industry. The company's flagship product is the Barostim Neo™ System, the world's first FDA-approved implantable device designed to manage cardiovascular conditions by leveraging the body's natural baroreflex mechanism.

CVRx has a significant presence in the United States, which accounts for the majority of its revenue. The company also operates internationally, including in Germany and other European countries, where its Barostim system has received CE Mark approval for both heart failure and resistant hypertension indications. As of December 31, 2025, CVRx reported 252 active implanting centers in the U.S. and 53 U.S. sales territories.

CVRx has actively engaged in educational initiatives and presented clinical evidence supporting its Barostim therapy, participating in major conferences and sponsoring an ACC infographic. Data presented showed significant real-world benefits of Barostim implantation, including a reduction in heart failure, cardiovascular, and all-cause hospital visits. However, the company's reputation may have been affected by recent investor alerts from law firms investigating potential securities fraud claims.

CVRx, Inc. has 180 institutional owners and shareholders, holding a total of 15,096,989 shares. Major institutional owners include Johnson & Johnson, NEA Management Company, LLC, Vanguard Group Inc, BlackRock, Inc., VTSMX - Vanguard Total Stock Market Index Fund Investor Shares, Balyasny Asset Management Llc, Parkman Healthcare Partners LLC, Morgan Stanley, Geode Capital Management, Llc and IWM - iShares Russell 2000 ETF.